SCHEMBL1604003

SCHEMBL1604003

Oc1ccc(-c2ccc(O)c(N=Nc3ccccc3O)c2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.59
KMT2A Q03164 3/20 0.59
KDM4E B2RXH2 1/20 0.59
NPC1 O15118 1/20 0.59
LMNA P02545 1/20 0.59
MAPT P10636 1/20 0.59
HTT P42858 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
L3MBTL1 Q9Y468 2/20 0.51
POLB P06746 1/20 0.51
ALOX5 P09917 2/20 0.50
MAOA P21397 1/20 0.50
MAOB P27338 1/20 0.50
ESR1 P03372 5/20 0.47
ESR2 Q92731 4/20 0.46
MGLL Q99685 1/20 0.45
MMP3 P08254 1/20 0.45
BCL2L1 Q07817 1/20 0.45
HSD17B1 P14061 2/20 0.44
HSD17B2 P37059 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL156635 0.91 MEN1 (0.61) MEN1KMT2AKDM4ENPC1LMNA
SCHEMBL31185843 0.89 MEN1 (0.59) MEN1KMT2AKDM4ENPC1LMNA
SCHEMBL28323616 0.84 MEN1 (0.70) MEN1KMT2AKDM4ENPC1LMNA
Alcohol SCHEMBL28276201 0.83 MEN1 (0.57) MEN1KMT2AKDM4ENPC1LMNA
SCHEMBL19970698 0.78 MEN1 (0.72) MEN1KMT2AKDM4ENPC1LMNA
SCHEMBL2855789 0.77 MEN1 (0.51) MEN1KMT2AKDM4ENPC1LMNA
SCHEMBL574042 0.77 MAPT (1.00) MEN1KMT2AKDM4ENPC1LMNA
SCHEMBL131175 0.77 MAPT (1.00) MEN1KMT2AKDM4ENPC1LMNA
SCHEMBL29354111 0.77 MAPT (1.00) MEN1KMT2AKDM4ENPC1LMNA
SCHEMBL10899974 0.76 MEN1 (0.70) MEN1KMT2AKDM4ENPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110082176-A1 Stilbenes and Chalcones for the Prevention and Treatment of Cardiovascular Diseases RESVERLOGIX CORP. 2011-04-07 US claimed
US-7846915-B2 Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases Resverlogix Corporation (CA) 2010-12-07 US claimed
US-8242144-B2 Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases RESVERLOGIX CORP. (CA) 2012-08-14 US disclosed
US-20110082176-A1 Stilbenes and Chalcones for the Prevention and Treatment of Cardiovascular Diseases RESVERLOGIX CORP. 2011-04-07 US disclosed
US-7846915-B2 Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases Resverlogix Corporation (CA) 2010-12-07 US disclosed
US-20060205792-A1 Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases HEPALINK (HONG KONG) LIMITED (HK) 2006-09-14 US disclosed
WO-2006045010-A2 STILBENES AND CHALCONES FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES RESVERLOGIX CORP. (CA) 2006-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060205792-A1 Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases APOB, APOL1, HDLBP MEN1 4636/4885KMT2A 3632/4885KDM4E 3450/4885
US-20110082176-A1 Stilbenes and Chalcones for the Prevention and Treatment of Cardiovascular Diseases APOB, APOL1, HDLBP MEN1 4636/4885KMT2A 3632/4885KDM4E 3450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.